Synthetic Human Secretin in Children With Autism

August 4, 2005 updated by: Repligen Corporation

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States
        • Southwest Autism Research Center
    • California
      • Los Angeles, California, United States, 90095-1752
        • UCLA Pediatric Neurology
      • Oakland, California, United States, 94609
        • Children's Hospital and Research Center at Oakland
    • Colorado
      • Centennial, Colorado, United States, 80112
        • 1st Allergy & Clinical Research Center
    • Florida
      • Gainesville, Florida, United States, 32607
        • Alachua Family Psychiatry
      • Miami, Florida, United States
        • Miami Children's Hospital
    • Indiana
      • Indianapolis, Indiana, United States, 46202-5200
        • Riley Children's Hospital
    • Louisiana
      • Metairie, Louisiana, United States, 70006
        • The Clinical Trials Center:A Division of Children's Hospital
    • Massachusetts
      • Hingham, Massachusetts, United States
        • Hardy Healthcare Associates
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Children's Hospital of Michigan
    • New Jersey
      • Newark, New Jersey, United States, 07107
        • University of Medicine and Dentistry of New Jersey
    • New York
      • New Hyde Park, New York, United States
        • Schneider Children's Hospital
    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University
    • Utah
      • Sandy, Utah, United States, 84093
        • Children's Biomedical Center of Utah
    • Washington
      • Edmonds, Washington, United States, 98026
        • Puget Sound Neurology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 4 years (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Autism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: DOUBLE

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Repligen Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2002

Study Completion

January 1, 2004

Study Registration Dates

First Submitted

May 8, 2002

First Submitted That Met QC Criteria

May 8, 2002

First Posted (ESTIMATE)

May 9, 2002

Study Record Updates

Last Update Posted (ESTIMATE)

August 5, 2005

Last Update Submitted That Met QC Criteria

August 4, 2005

Last Verified

August 1, 2005

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RG1068-04

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism

Clinical Trials on RG1068 (Synthetic Human Secretin)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe